Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) Following Appreciation

32 minutes ago 1

Soumya Eswaran

Mon, December 1, 2025 astatine 7:04 AM CST 3 min read

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Equities deed a grounds precocious successful the 3rd quarter, fueled by continued gains successful exertion and falling enslaved yields. Easing tariff rhetoric and renewed AI infrastructure investments boosted ample tech stocks. In mid-September U.S. Federal Reserve lowered rates by 25 ground points. Against this backdrop, the money returned -1.78% (net) compared to the Russell 2500 Growth Index’s 10.73% return. Sector positioning and the avoidance of names that bash not conscionable the firm’s strict concern subject led to the underperformance of the money successful the quarter. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Meridian Growth Fund highlighted stocks specified arsenic Halozyme Therapeutics, Inc. (NASDAQ:HALO). Halozyme Therapeutics, Inc. (NASDAQ:HALO) is simply a atomic substance supplying company. The one-month instrumentality of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was 7.85%, and its shares gained 46.94% of their worth implicit the past 52 weeks. On November 28, 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) banal closed astatine $71.40 per share, with a marketplace capitalization of $8.396 billion.

Meridian Growth Fund stated the pursuing regarding Halozyme Therapeutics, Inc. (NASDAQ:HALO) successful its 3rd 4th 2025 capitalist letter:

"Halozyme Therapeutics, Inc. (NASDAQ:HALO) is simply a starring cause transportation level institution built astir its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous transportation of biologics and fluids, transforming hours-long intravenous infusions into speedy injections delivered successful minutes. The exertion reduces attraction load for patients and alleviates capableness constraints for healthcare providers. Halozyme reported a beardown quarter, with royalty revenues up 65% and continued uptake of its drugs, on with expanding use-case indications from its pharmaceutical partners. Management raised full-year guidance for some revenues and earnings, which was well-received by investors. During the period, we trimmed our presumption arsenic the stock terms appreciated, accordant with our disciplined valuation approach."

Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest successful Now?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge money portfolios held Halozyme Therapeutics, Inc. (NASDAQ:HALO) astatine the extremity of the 3rd quarter, which was 40 successful the erstwhile quarter. In Q3 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported full gross of $354 million, representing 22% maturation year-over-year. While we admit the imaginable of Halozyme Therapeutics, Inc. (NASDAQ:HALO) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.